Update on the merger approval process for the combination of Novozymes and Chr. Hansen: The parties have submitted a remedy proposal to the European Commission.

November 20, 2023

Please see attachment.

Contact information

Investor Relations
Anders Mohr Christensen
+45 2515 2364
dkamc@chr-hansen.com

Press Relations
Sanne Seyer-Hansen
+45 6038 6207
dksash@chr-hansen.com

Attachment

• 2023_Update on the merger approval process for the combination of Novozymes and Chr. Hansen